Subtler scopes: Where IRA drug negotiations meet Part D redesigns
Understanding how the IRA’s multiple provisions interact to induce cost-related change The Inflation Reduction Act (IRA) ushers in numerous changes for the pharmaceutical sector. The law is…
Read the full articleYou might also wanna read
Medicare's 2025: A New Landscape for Senior Healthcare
In 2025, Medicare introduced significant changes to enhance senior healthcare. Notably, there will be a $2,000 annual cap on out-of-pocket p
CMS Proposed Rule Locks in Lower Prices and Fosters Innovation for the Medicare Drug Price Negotiation Program
CMS Proposed Rule Locks in Lower Prices and Fosters Innovation for the Medicare Drug Price Negotiation Program
Most-Favored Nation Drug Pricing: What U.S. Pricing Initiatives Mean for International Commercial Contracts
The Trump administration’s most-favored nation agreements with major pharmaceutical companies and recent initiatives by the Centers for Medi
From Constitutional Attack to Statutory Combat: The Next Wave of Medicare Drug-Price Litigation
By: Jimmie L. Bullock Background On May 18, 2026, the Supreme Court declined to review six pharmaceutical manufacturers’ challenges to the M
How Seniors Can Lower Medicare Drug Costs in 2026
Learn how 2026 Medicare Part D caps, federal programs, negotiated prices, and newer options like TrumpRx may affect drug costs for seniors a
STAT+: Medicare takes another swing at 340B cuts to hospitals
Reducing Medicare payments for 340B drugs is the latest proposal focused on the hotly debated drug discount program.
Comments
Sign in to join the conversation.
No comments yet. Be the first.